[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362211-105":59,"doc-detail-362211-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","jiang-et-al-breast-cancer-research-2026-2810-research-open-access-bhlhe22-targeted-by-otud3-exerts-an-antitumor-role-in-triple-negative-breast-cancer-progression","Jiang et al. Breast Cancer Research (2026) 28:10 - Research Open Access - BHLHE22 targeted by OTUD3 exerts an antitumor role in triple-negative breast cancer progression","","BHLHE22, a basic helix-loop-helix transcription factor, shows distinct functions across cancer types, yet its role in triple-negative breast cancer (TNBC) remains unclear. Using GEO datasets and expression/prognostic analyses, the study links reduced BHLHE22 in TNBC to worse outcomes. Functional work in vitro and in vivo demonstrates that BHLHE22 overexpression suppresses malignant cell growth, whereas silencing promotes malignancy. Mechanistically, OTUD3 increases BHLHE22 stability via deubiquitination, and BHLHE22 inhibits CDT1 transcription to mediate the antitumor effect.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/jiang-et-al-breast-cancer-research-2026-2810-research-open-access-bhlhe22-targeted-by-otud3-exerts-an-antitumor-role-in-triple-negative-breast-cancer-progression/362211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/jiang-et-al-breast-cancer-research-2026-2810-research-open-access-bhlhe22-targeted-by-otud3-exerts-an-antitumor-role-in-triple-negative-breast-cancer-progression/362211.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does BHLHE22 play in triple-negative breast cancer (TNBC)?","Question",{"text":112,"@type":113},"The findings show BHLHE22 is downregulated in TNBC tissues, and higher BHLHE22 expression is associated with better survival. Functionally, BHLHE22 overexpression impairs TNBC cell growth, while silencing enhances malignant behaviors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is OTUD3 related to BHLHE22 regulation?",{"text":117,"@type":113},"OTUD3 is shown to increase BHLHE22 protein stability through deubiquitination. A site-specific OTUD3 C76 mutation disrupts OTUD3 catalytic activity and fails to regulate BHLHE22 stability.",{"name":119,"@type":110,"acceptedAnswer":120},"How does BHLHE22 exert its antitumor effect mechanistically?",{"text":121,"@type":113},"BHLHE22 transcriptionally inhibits CDT1 by blocking CDT1 transcription. The anti-proliferative effect of BHLHE22 overexpression is reversed by CDT1 overexpression, supporting a BHLHE22→CDT1 axis in TNBC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362211,1790177300,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Jiang et al. Breast Cancer Research (2026) 28:10 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02198-0](https://doi.org/10.1186/s13058-025-02198-0)  \nRESEARCH Open Access  \nBHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1  \nLei Jiang1, Junnan Xu1, Cui Jiang1, Yufeng Jia1, Ye Zhang2* and Tao Sun1*  \nAbstract  \nBackground Basic helix-loop-helix family, member e22 (BHLHE22), a basic helix loop helix transcription factor family member, functions vary in different types of cancer. Currently, its function in triple-negative breast cancer (TNBC) is unclear.  \nMethods The GSE45827 and GSE113865 datasets were used to screen potential TNBC marker. Biological websites were used to analyze BHLHE22 expression inTNBC, its relationship with the prognosis of patients with TNBC, and its potential function. A series of in vitro and in vivo experiments was performed to investigate the function of BHLHE22 inTNBC. The regulatory relationship between OTU domain-containing protein 3 (OTUD3) and BHLHE22 was verified by Co-Immunoprecipitation, ubiquitination assay, and site-specific mutation experiments. The mRNA-seq analysis was performed to identify potential genes for the anti-cancer role of BHLHE22 . The transcriptional regulation of DNA replication factor 1 (CDT1) by BHLHE22 was confirmed by dual luciferase reporter assay.  \nResults We identified the downregulation of BHLHE22 inTNBC tissues based on the GSE45827 and GSE113865 datasets. The expression of BHLHE22 in TBNC patients was lower than that in non-TNBC patients, and patients at stages 3 and 4 tended to express lower BHLHE22 expression than patients at stages 1 and 2. Patients with high expression of BHLHE22 had better survival prognosis than those with BHLHE22 low expression. Functional studies revealed that BHLHE22 overexpression impaired cell growth in vitro and in vivo. However, BHLHE22 silencing enhanced the malignant behaviors of cancer cells. OTUD3, a deubiquitinase known to suppress TNBC progression, was found to increase the stability of BHLHE22 protein through deubiquitination regulation. The C76 site mutation of OTUD3 eliminated the catalytic activity of OTUD3 and failed to regulate the protein stability of BHLHE22 . Furthermore, BHLHE22 medicated the antitumor effect of OTUD3 inTNBC. The mRNA-seq analysis identified potential genes for the anti-cancer role of BHLHE22, involving CDT1 . BHLHE22 was proved to reduce CDT1 RNA expression by blocking CDT1 transcription. The anti-proliferative effect of BHLHE22 overexpression was reversed by CDT1 overexpression.  \n*Correspondence: Ye Zhang [zhangyecmu@163.com](zhangyecmu@163.com)[ ](zhangyecmu@163.com)Tao Sun [jianong@126.com](jianong@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.o","cbCaigdrJZIPhVIa","https://ap.wps.com/l/cbCaigdrJZIPhVIa","pdf",14098576,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What role does BHLHE22 play in triple-negative breast cancer (TNBC)?\",\"answer\":\"The findings show BHLHE22 is downregulated in TNBC tissues, and higher BHLHE22 expression is associated with better survival. Functionally, BHLHE22 overexpression impairs TNBC cell growth, while silencing enhances malignant behaviors.\"},{\"question\":\"How is OTUD3 related to BHLHE22 regulation?\",\"answer\":\"OTUD3 is shown to increase BHLHE22 protein stability through deubiquitination. A site-specific OTUD3 C76 mutation disrupts OTUD3 catalytic activity and fails to regulate BHLHE22 stability.\"},{\"question\":\"How does BHLHE22 exert its antitumor effect mechanistically?\",\"answer\":\"BHLHE22 transcriptionally inhibits CDT1 by blocking CDT1 transcription. The anti-proliferative effect of BHLHE22 overexpression is reversed by CDT1 overexpression, supporting a BHLHE22→CDT1 axis in TNBC.\"}]","Jiang et al. Breast Cancer Research (2026) 28:10 - Research Open Access - BHLHE22 targeted by OTUD3 exerts an antitumor role in triple-negative breast cancer progression | PDF",1790146791,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c14aafab126818ea73df3884476006b.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6faae5f8863b1cf8bb123e1299d36963.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13d80af6353c434980d20387dedc2034.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0367eca5335d9e5564539c6313a3a172.webp",980,1306]